← Back to patent-cliff list
TER-2013
Tier C — Watch / tradeTER-2013
Terremoto Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AKT1
Indications (approved)：Cervical cancer, Squamous cell carcinoma, Ovarian cancer, Breast cancer, Solid tumour, 食管鳞状细胞癌, Head and neck squamous cell carcinoma, Endometrial cancer
Regional status
US
Phase II
2025-09-23
EU
Phase II
2025-09-23
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TER-2013?
Approved indications include: Cervical cancer, Squamous cell carcinoma, Ovarian cancer, Breast cancer, Solid tumour, 食管鳞状细胞癌, Head and neck squamous cell carcinoma, Endometrial cancer.
When does the TER-2013 patent expire?
No public expiry year is available for TER-2013 yet; this page updates once verified.
How do I get a quote for TER-2013 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30